(Q38430744)

3 September 2017

1 reference

title

Statin intolerance: diagnosis and remedies (English)

1 reference

3 September 2017

1 reference

ChEBI release 2020-05-28

2

1 reference

3 September 2017

Angela Pirillo

1

0 references

language of work or name

1 reference

1 May 2015

1 reference

Current cardiology reports

3 September 2017

published in

1 reference

3 September 2017

volume

17

1 reference

3 September 2017

issue

5

1 reference

3 September 2017

page(s)

27

1 reference

Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Narrative review: statin-related myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Statin safety: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Statin myopathy: a common dilemma not reflected in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Needed: pragmatic clinical trials for statin-intolerant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Phenotype standardization for statin-induced myotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Effect of statins on skeletal muscle function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

The role of coenzyme Q10 in statin-associated myopathy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Toxicity of statins on rat skeletal muscle mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Cerivastatin and reports of fatal rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Prevalence of the prescription of potentially interacting drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

A clinician's guide to statin drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Safety and efficacy of statins in Asians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Statin myotoxicity: a review of genetic susceptibility factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

SLCO1B1 variants and statin-induced myopathy--a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

SLCO1B1 Polymorphisms and Statin-Induced Myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Statin therapy correlated CYP2D6 gene polymorphism and hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Genetic risk factors associated with lipid-lowering drug-induced myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Discontinuation of statins in routine care settings: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Treating statin-intolerant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

The high-dose rosuvastatin once weekly study (the HD-ROWS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Non-every day statin administration--a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Alternate-day dosing with statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery dis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Emerging LDL therapies: Mipomersen-antisense oligonucleotide therapy in the management of hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Lipid-lowering efficacy of red yeast rice in a population intolerant to statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Berberine decreases PCSK9 expression in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0582-Z

In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes

21 January 2018

1 reference

12 December 2020

Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes.

1 reference

12 December 2020

No association between CYP3A4*22 and statin effectiveness in reducing the risk for myocardial infarction

1 reference

12 December 2020

Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: a subanalysis of the USAGE study

1 reference

12 December 2020

Statins for the primary prevention of cardiovascular disease

1 reference

12 December 2020

Discontinuation of statin therapy due to muscular side effects: a survey in real life

1 reference

12 December 2020

The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials

1 reference

12 December 2020

10.1007/S11886-015-0582-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

1028652910

0 references

1 reference